CN116390737A - 用于治疗癌症的包括丁酸梭菌的组合物和方法 - Google Patents

用于治疗癌症的包括丁酸梭菌的组合物和方法 Download PDF

Info

Publication number
CN116390737A
CN116390737A CN202180044054.6A CN202180044054A CN116390737A CN 116390737 A CN116390737 A CN 116390737A CN 202180044054 A CN202180044054 A CN 202180044054A CN 116390737 A CN116390737 A CN 116390737A
Authority
CN
China
Prior art keywords
dose
cancer
clostridium butyricum
cfu
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044054.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·P·李
S·K·帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN116390737A publication Critical patent/CN116390737A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180044054.6A 2020-04-21 2021-04-20 用于治疗癌症的包括丁酸梭菌的组合物和方法 Pending CN116390737A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013141P 2020-04-21 2020-04-21
US63/013,141 2020-04-21
PCT/US2021/028251 WO2021216618A1 (en) 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN116390737A true CN116390737A (zh) 2023-07-04

Family

ID=78270016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044054.6A Pending CN116390737A (zh) 2020-04-21 2021-04-20 用于治疗癌症的包括丁酸梭菌的组合物和方法

Country Status (8)

Country Link
US (1) US12589123B2 (enExample)
EP (1) EP4138869A4 (enExample)
JP (2) JP7813240B2 (enExample)
KR (1) KR20230004604A (enExample)
CN (1) CN116390737A (enExample)
AU (1) AU2021261290A1 (enExample)
CA (1) CA3180564A1 (enExample)
WO (1) WO2021216618A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116650534A (zh) * 2023-03-10 2023-08-29 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN120131715A (zh) * 2025-03-14 2025-06-13 中山大学孙逸仙纪念医院 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415900A1 (en) * 2021-10-20 2024-12-19 City Of Hope Clostridium butyricum compositions and methods of using the same
CN115671142A (zh) * 2022-11-15 2023-02-03 中山大学附属第六医院 丁酸梭菌在结直肠癌辅助治疗上的应用
CN121152637A (zh) * 2023-05-23 2025-12-16 日本米雅利桑制药株式会社 癌治疗用组合药物
CN116687979B (zh) * 2023-06-28 2025-06-20 中国人民解放军陆军军医大学 肠道微生物在稳定肠道谷氨酰胺以及在制备治疗癌症的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269836A (ja) * 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
CN109771445A (zh) * 2019-03-20 2019-05-21 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153219A (ja) 1984-08-23 1986-03-17 Tadashi Arai 抗腫瘍剤
EP3518946A4 (en) * 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269836A (ja) * 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies
CN109771445A (zh) * 2019-03-20 2019-05-21 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116650534A (zh) * 2023-03-10 2023-08-29 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN116650534B (zh) * 2023-03-10 2026-07-28 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN120131715A (zh) * 2025-03-14 2025-06-13 中山大学孙逸仙纪念医院 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用

Also Published As

Publication number Publication date
JP2026031928A (ja) 2026-02-25
US12589123B2 (en) 2026-03-31
EP4138869A4 (en) 2024-05-15
JP2023522716A (ja) 2023-05-31
US20230149479A1 (en) 2023-05-18
EP4138869A1 (en) 2023-03-01
KR20230004604A (ko) 2023-01-06
AU2021261290A1 (en) 2022-11-03
JP7813240B2 (ja) 2026-02-12
WO2021216618A1 (en) 2021-10-28
CA3180564A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12589123B2 (en) Compositions and methods comprising clostridium butyricum for the treatment of cancer
US20230263843A1 (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
KR102711178B1 (ko) 결장직장암의 치료를 위한 박테리아 및 세포 조성물, 및 이를 갖는 환자의 예후를 평가하는 방법
EP3209692B1 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
KR102464342B1 (ko) 화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도
US20190092875A1 (en) Depleting tumor-specific tregs
TW201717975A (zh) 藉由控制共生微生物叢來治療癌症
US20230338438A1 (en) Bacterial biofilms and cancer
KR20220116438A (ko) 암 치료를 위한 미생물총 및 대사산물의 힘 활용
JP7750871B2 (ja) 治療用細菌組成物
WO2025072639A1 (en) Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same
CN113905749A (zh) 用于治疗免疫检查点抑制剂相关结肠炎的方法和组合物
WO2023069655A1 (en) Clostridium butyricum compositions and methods of using the same
US20230002502A1 (en) Methods and products for reducing side effects associated with use of immune agonist antibodies
WO2026104810A1 (en) Isolated bacteria or culture supernatants thereof for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination